Management of patients with low-stage nonseminomatous germ cell testicular cancer

Current Treatment Options in Oncology

Volumn 6, Issue 5, 2005, Pages 367-377

  Stephenson, Andrew J ^a   Sheinfeld, Joel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; TUMOR MARKER;

AUTOPSY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; EJACULATION DISORDER; HUMAN; INFERTILITY; INTERMETHOD COMPARISON; KIDNEY DISEASE; LAPAROSCOPY; LEUKEMIA; LUNG TOXICITY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MALE FERTILITY; METASTASIS POTENTIAL; METHODOLOGY; MORBIDITY; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; OTOTOXICITY; PARAAORTIC LYMPH NODE; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; POSTOPERATIVE CARE; PROGNOSIS; RAYNAUD PHENOMENON; RETROPERITONEAL DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SURGICAL TECHNIQUE; SURVIVAL TIME; TESTIS CANCER; THORAX RADIOGRAPHY; TREATMENT OUTCOME; VISCERAL METASTASIS;

EID: 28044468001     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-005-0040-z     Document Type: Review

References (68)

1. Sheinfeld J, McKiernan J, Bosl GJ, eds: Surgery of testicular tumors. In Campbell's Urology, edn 8. Edited by Walsh PC, Retik AB, Vaughn ED, Wein AJ, eds. Philadelphia: WB Saunders; 2002: 2920-2944.
2. Greene FL, Page DL, Fleming ID, et al., eds: In AJCC Cancer Staging Manual, edn 6. New York: Springer Verlag; 2002: 131-144.
3. Stephenson AJ, Bosl GJ, Bajorin DF, et al.: Retroperitoneal lymph node dissection for low-stage testicular cancers patients with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol 2005, 174: 557-560.
4. Stephenson AJ, Bosl GJ, Motzer RJ et al.: Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 2005, 23:2781-2788.
5. Richie JP: Clinical stage 1 testicular cancer: the role of modified retroperitoneal lymphadenectomy. J Urol 1990, 144:1160-1163.
6. Nicolai N, Miceli R, Artusi R, et al.: A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only. J Urol 2004, 171:172-176.
7. Hermans BP, Sweeney CJ, Foster RS, et al.: Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urol 2000, 163:1721-1724.
8. Donohue JP, Thornhill JA, Foster RS, et al.: Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol 1993, 149:237-243.
9. Daugaard G, Petersen PM, Rorth M: Surveillance in stage I testicular cancer [discussion 83-85]. APMIS 2003, 111:76-83.
10. Sogani PC, Perrotti M, Herr HW, et al.: Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol 1998, 159:855-858.
11. Pizzocaro G, Zanoni F, Salvioni R, et al.: Difficulties of a surveillance study omitting retroperitoneal lymphadenectomy in clinical stage I nonseminomatous germ cell tumors of the testis. J Urol 1987, 138:1393-1396.
12. Alexandre J, Fizazi K, Mahe C, et al.: Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse. Eur J Cancer 2001, 37:576-582.
13. Gels ME, Hoekstra HJ, Sleijfer DT, et al.: Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol 1995, 13:1188-1194.
14. Sturgeon JF, Jewett MA, Alison RE, et al.: Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors. J Clin Oncol 1992, 10:564-568.
15. Read G, Stenning SP, Cullen MH, et al.: Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992, 10:1762-1768.
16. Hao D, Seidel J, Brant R, Alexander F, Ernst DS, Summers N, et al.: Compliance of clinical stage I nonseminomatous germ cell tumor patients with surveillance. J Urol 1998, 160:768-771.
17. Freedman LS, Parkinson MC, Jones WG, et al.: Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 1987, 2:294-298.
18. Amato RJ, Ro JY, Ayala AG, Swanson DA: Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis [discussion 148-149]. Urology 2004, 63:144-148.
19. Bohlen D, Borner M, Sonntag RW, et al.: Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 1999, 161:1148-1152.
20. Cullen MH, Stenning SP, Parkinson MC, et al.: Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 1996, 14:1106-1113.
21. Oliver RT, Ong J, Shamash J, et al.: Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. Urology 2004, 63:556-561.
22. Pont J, Albrecht W, Postner G, et al.: Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996, 14:441-448.
23. Sheinfeld J: Nonseminomatous germ cell tumors of the testis: current concepts and controversies. Urology 1994, 44:2-14.
24. Donohue JP, Zachary JM, Maynard BR: Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 1982, 128:315-320.
25. Fernandez EB, Moul JW, Foley JP, et al.: Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors. Urology 1994, 44:548-552.
26. Albers P, Siener R, Kliesch S, et al.: Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 2003, 21:1505-1512.
27. Heidenreich A, Sesterhenn IA, Mostofi FK, Moul JW: Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 1998, 83:1002-1011.
28. Bredael JJ, Vugrin D, Whitmore WF, Jr: Autopsy findings in 154 patients with germ cell tumors of the testis. Cancer 1982, 50:548-551.
29. Foster RS, Baniel J, Leibovitch I, et al.: Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in low stage nonseminomatous testis cancer. J Urol 1996, 155:1943-1945.
30. Sheinfeld J, Motzer RJ, Rabbani E et al.: Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors. J Urol 2003, 170:1159-1162.
31. Logothetis CJ, Samuels ML, Trindade A, Johnson DE: The growing teratoma syndrome. Cancer 1982, 50:1629-1635.
32. Motzer RJ, Amsterdam A, Prieto V, et al.: Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol 1998, 159:133-138.
33. Sheinfeld J: Late recurrence of testicular cancer. AUA News 2001, 6:12-14.
34. Baniel J, Foster RS, Gonin R, et al.: Late relapse of testicular cancer. J Clin Oncol 1995, 13:1170-1176.
35. George DW, Foster RS, Hromas RA, et al.: Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol 2003, 21:113-122.
36. Sheinfeld J: Risks of the uncontrolled retroperitoneum. Ann Surg Oncol 2003, 10: 100-101.
37. Stephenson AJ, Bosl GJ, Bajorin DF, et al.: Primary retroperitoneal lymph node dissection (P-RPLND) versus induction chemotherapy (IC) for the management of clinical stage (CS) IIA and IIB nonseminomatous germ cell testicular cancer (NSGCT) [abstract]. J Urol 2005, 173 (4 Suppl): 196.
38. Swanson DA, von Eschenbach AC, Babaian RJ, et al.: Is retroperitoneal lymph node dissection (RPLND) alone optimal or sufficient therapy for clinical stage I nonseminomatous germ cell testicular tumors (NSGCTT) at high risk for relapse? J Urol 1998, 158:179A.
39. Williams SD, Stablein DM, Einhorn LH, et al.: Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 1987, 317:1433-1438.
40. Donohue JP, Thornhill JA, Foster RS, et al.: Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer 1995, 31A: 1599-1604.
41. Vogelzang NJ, Fraley EE, Lange PH, et al.: Stage II nonseminomatous testicular cancer: a 10-year experience. J Clin Oncol 1983, 1:171-178.
42. Socinski MA, Garnick MB, Stomper PC, et al.: Stage II nonseminomatous germ cell tumors of the testis: an analysis of treatment options in patients with low volume retroperitoneal disease. J Urol 1988, 140:1437-1441.
43. Javadpour N, Young JD, Jr: Prognostic factors in nonseminomatous testicular cancer. J Urol 1986, 135:497-499.
44. Pizzocaro G, Monfardini S: No adjuvant chemotherapy in selected patients with pathologic stage II nonseminomatous germ cell tumors of the testis. J Urol 1984, 131:677-680.
45. Kondagunta GV, Sheinfeld J, Mazumdar M, et al.: Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol 2004, 22:464-467.
46. Baniel J, Foster RS, Rowland RG, et al.: Complications of primary retroperitoneal lymph node dissection. J Urol 1994, 152:424-427.
47. McLeod DG, Weiss RB, Stablein DM, et al.: Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study [discussion 1182-1183]. J Urol 1991, 145:1178-1183.
48. Sheinfeld J: Complications of retroperitoneal lymph node dissection. AUA News 2002, 7:10-14.
49. Donohue JP, Foster RS: Retroperitoneal lymphadenectomy in staging and treatment. The development of nerve-sparing techniques. Urol Clin North Am 1998, 25:461-468.
50. Jewett MA, Kong YS, Goldberg SD, et al.: Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol 1988, 139:1220-1224.
51. Jewett MA: Nerve-sparing technique for retroperitoneal lymphadenectomy in testis cancer. Urol Clin North Am 1990, 17:449-456.
52. Bhayani SB, Ong A, Oh WK, et al.: Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. Urology 2003, 62:324-327.
53. Janetschek G, Hobisch A, Peschel R, et al.: Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome. J Urol 2000, 163:1793-1796.
54. Nelson JB, Chen RN, Bishoff JT, et al.: Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. Urology 1999, 54:1064-1067.
55. Janetschek G: Laparoscopic retroperitoneal lymph node dissection. Urol Clin North Am 2001, 28:107-114.
56. Steiner H, Peschel R, Janetschek G, et al.: Long-term results of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience. Urology 2004, 63:550-555.
57. Peschel R, Gettman MT, Neururer R, et al.: Laparoscopic retroperitoneal lymph node dissection: description of the nerve-sparing technique [discussion 343]. Urology 2002, 60:339-343.
58. Bajorin DF, Sarosdy MF, Pfister DG, et al.: Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993, 11:598-606.
59. Howard GC, Clarke K, Elia MH, et al.: A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ-cell tumours. The Scottish Radiological Society and the Scottish Committee of the Royal College of Radiologists. Br J Cancer 1995, 72:1303-1306.
60. Leibovitch L, Foster RS, Kopecky KK, Donohue JP: Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. J Urol 1995, 154:1759-1763.
61. Hilton S, Herr HW, Teitcher JB, et al.: CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. AJR Am J Roentgenol 1997, 169:521-525.
62. Behnia M, Foster R, Einhorn LH, et al.: Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer the Indiana University experience. Eur J Cancer 2000, 36:472-475.
63. Kollmannsberger C, Kuzcyk M, Mayer F, et al.: Late toxicity following curative treatment of testicular cancer. Semin Surg Oncol 1999, 17:275-281.
64. Boyer M, Raghavan D: Toxicity of treatment of germ cell tumors. Semin Oncol 1992, 19:128-142.
65. Meinardi MT, Gietema JA, van der Graaf WT, et al.: Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000, 18:1725-1732.
66. Bajorin DF, Motzer RJ, Rodriguez E, et al.: Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 1993, 85:60-62.
67. Huddart RA, Norman A, Shahidi M, et al.: Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003, 21:1513-1523.
68. Nichols CR, Roth BJ, Williams SD, et al.: No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: an analysis of the Testicular Cancer Intergroup Study. J Clin Oncol 1992, 10:760-765.